471 related articles for article (PubMed ID: 25441438)
1. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.
Inker LA; Lambers Heerspink HJ; Mondal H; Schmid CH; Tighiouart H; Noubary F; Coresh J; Greene T; Levey AS
Am J Kidney Dis; 2014 Dec; 64(6):848-59. PubMed ID: 25441438
[TBL] [Abstract][Full Text] [Related]
2. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.
Lambers Heerspink HJ; Tighiouart H; Sang Y; Ballew S; Mondal H; Matsushita K; Coresh J; Levey AS; Inker LA
Am J Kidney Dis; 2014 Dec; 64(6):860-6. PubMed ID: 25441439
[TBL] [Abstract][Full Text] [Related]
3. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study.
Greene T; Teng CC; Inker LA; Redd A; Ying J; Woodward M; Coresh J; Levey AS
Am J Kidney Dis; 2014 Dec; 64(6):867-79. PubMed ID: 25441440
[TBL] [Abstract][Full Text] [Related]
4. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
Levey AS; Inker LA; Matsushita K; Greene T; Willis K; Lewis E; de Zeeuw D; Cheung AK; Coresh J
Am J Kidney Dis; 2014 Dec; 64(6):821-35. PubMed ID: 25441437
[TBL] [Abstract][Full Text] [Related]
5. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
[TBL] [Abstract][Full Text] [Related]
6. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.
Badve SV; Palmer SC; Hawley CM; Pascoe EM; Strippoli GF; Johnson DW
Nephrol Dial Transplant; 2016 Sep; 31(9):1425-36. PubMed ID: 26163881
[TBL] [Abstract][Full Text] [Related]
7. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Levey AS; Gansevoort RT; Coresh J; Inker LA; Heerspink HL; Grams ME; Greene T; Tighiouart H; Matsushita K; Ballew SH; Sang Y; Vonesh E; Ying J; Manley T; de Zeeuw D; Eckardt KU; Levin A; Perkovic V; Zhang L; Willis K
Am J Kidney Dis; 2020 Jan; 75(1):84-104. PubMed ID: 31473020
[TBL] [Abstract][Full Text] [Related]
8. Renal end points in clinical trials of kidney disease.
Weldegiorgis M; de Zeeuw D; Heerspink HJ
Curr Opin Nephrol Hypertens; 2015 May; 24(3):284-9. PubMed ID: 25887898
[TBL] [Abstract][Full Text] [Related]
9. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.
Coresh J; Turin TC; Matsushita K; Sang Y; Ballew SH; Appel LJ; Arima H; Chadban SJ; Cirillo M; Djurdjev O; Green JA; Heine GH; Inker LA; Irie F; Ishani A; Ix JH; Kovesdy CP; Marks A; Ohkubo T; Shalev V; Shankar A; Wen CP; de Jong PE; Iseki K; Stengel B; Gansevoort RT; Levey AS
JAMA; 2014 Jun; 311(24):2518-2531. PubMed ID: 24892770
[TBL] [Abstract][Full Text] [Related]
10. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID
Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
[TBL] [Abstract][Full Text] [Related]
11. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.
Inker LA; Heerspink HJL; Tighiouart H; Levey AS; Coresh J; Gansevoort RT; Simon AL; Ying J; Beck GJ; Wanner C; Floege J; Li PK; Perkovic V; Vonesh EF; Greene T
J Am Soc Nephrol; 2019 Sep; 30(9):1735-1745. PubMed ID: 31292197
[TBL] [Abstract][Full Text] [Related]
12. Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR.
Matsushita K; Tonelli M; Lloyd A; Levey AS; Coresh J; Hemmelgarn BR;
Am J Kidney Dis; 2012 Aug; 60(2):241-9. PubMed ID: 22560843
[TBL] [Abstract][Full Text] [Related]
13. GFR decline as an end point for clinical trials in CKD: a view from Europe.
Mol PG; Maciulaitis R; Vetter T
Am J Kidney Dis; 2014 Dec; 64(6):838-40. PubMed ID: 25455092
[No Abstract] [Full Text] [Related]
14. Short-term change in kidney function and risk of end-stage renal disease.
Turin TC; Coresh J; Tonelli M; Stevens PE; de Jong PE; Farmer CK; Matsushita K; Hemmelgarn BR
Nephrol Dial Transplant; 2012 Oct; 27(10):3835-43. PubMed ID: 22764191
[TBL] [Abstract][Full Text] [Related]
15. GFR decline as an alternative end point in clinical trials to prevent ESRD: are we increasing treatment uncertainty for the sake of feasibility?
Sontrop JM; Al-Jaishi AA; Garg AX
Am J Kidney Dis; 2014 Dec; 64(6):841-4. PubMed ID: 25455093
[No Abstract] [Full Text] [Related]
16. The impact of self-management support on the progression of chronic kidney disease--a prospective randomized controlled trial.
Chen SH; Tsai YF; Sun CY; Wu IW; Lee CC; Wu MS
Nephrol Dial Transplant; 2011 Nov; 26(11):3560-6. PubMed ID: 21414969
[TBL] [Abstract][Full Text] [Related]
17. Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.
Greene T; Ying J; Vonesh EF; Tighiouart H; Levey AS; Coresh J; Herrick JS; Imai E; Jafar TH; Maes BD; Perrone RD; Del Vecchio L; Wetzels JFM; Heerspink HJL; Inker LA
J Am Soc Nephrol; 2019 Sep; 30(9):1756-1769. PubMed ID: 31292198
[TBL] [Abstract][Full Text] [Related]
18. Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study.
Kanda E; Usui T; Kashihara N; Iseki C; Iseki K; Nangaku M
Clin Exp Nephrol; 2018 Apr; 22(2):318-327. PubMed ID: 28884361
[TBL] [Abstract][Full Text] [Related]
19. Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality.
Xie Y; Bowe B; Xian H; Balasubramanian S; Al-Aly Z
Am J Kidney Dis; 2016 Aug; 68(2):219-228. PubMed ID: 26948835
[TBL] [Abstract][Full Text] [Related]
20. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
